

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zylox-Tonbridge Medical Technology Co., Ltd.

歸創通橋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2190)

VOLUNTARY ANNOUNCEMENT NATIONAL MEDICAL PRODUCTS ADMINISTRATION GRANTED MARKETING APPROVAL FOR ZYLOX® PENGUIN PERIPHERAL VENOUS STENT SYSTEM

This announcement is made by Zylox-Tonbridge Medical Technology Co., Ltd. (the “**Company**”, together with its subsidiary, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development of the Group.

The Company is pleased to announce that the ZYLOX® Penguin Peripheral Venous Stent System, self-developed by the Group, has recently been granted marketing approval by the National Medical Products Administration (the “**NMPA**”). This marks another milestone in the Company’s deployment of a total solution for interventional treatment of peripheral venous diseases and further strengthens its market position and influence in the field of peripheral vascular intervention. As of the date of this announcement, the Company has obtained approvals from the NMPA for a total of 36 products in the People’s Republic of China (the “**PRC**”).

ZYLOX® Penguin Peripheral Venous Stent System is an innovative product developed by the medical-industrial joint effort of the Group in cooperation with the First Affiliated Hospital of Chongqing Medical University. The product has 8 invention patents and is designed for lower limb and pelvic venous return disorders caused by iliac vein compression. The ZYLOX® Penguin Peripheral Venous Stent System, featuring three major designs of oblique entrance, tapered gradient and integrated structure, is designed to reduce the risk of thrombosis while ensuring alignment with the natural variation of dimension of the blood vessel. The ZYLOX® Penguin Peripheral Venous Stent System is designed to provide excellent wall adherence and gradual expansion, with a proximal closed-loop structure for strong support and a distal open-loop structure for excellent alignment.

The pre-market clinical trial of the ZYLOX® Penguin Peripheral Venous Stent System was led by Professor Zhao Yu of the First Affiliated Hospital of Chongqing Medical University. A total of 161 patients from 14 top clinical trial centers across the PRC were enrolled over a period of 10 months, with the target vessel patency rate reaching 100% at 12 months after the procedure. Such excellent clinical trial results strongly demonstrate the safety and efficacy of this product.

Iliac Vein Compression Syndrome (“IVCS”) is a blood circulation disorder caused by compression of the iliac veins. The main symptoms include leg pain and swelling, occasionally accompanied by deep vein thrombosis. Treatment paradigm of IVCS mainly includes medication, surgery and vascular intervention. Currently, interventional therapy using peripheral venous stents has become the main method of treatment for IVCS.

As disclosed in the prospectus of the Company dated June 22, 2021, the potential incidence of IVCS in the PRC is expected to reach 2.0 million by 2030; meanwhile, the number of peripheral venous stent interventional procedures is expected to grow at a compound annual growth rate of nearly 50% from 2019 to 2030. With the launch of the ZYLOX® Penguin Peripheral Venous Stent System, the Company believes that it will bring domestic innovative iliac vein compression treatment solutions to patients in the PRC with higher quality and accessibility.

By order of the board
Zylox-Tonbridge Medical Technology Co., Ltd.
Dr. Jonathon Zhong Zhao
Chairman and Executive Director

Hong Kong, January 22, 2024

As of the date of this announcement, the board of directors of the Company comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive directors, Mr. Stephen Hui Wang, Dr. Steven Dasong Wang and Mr. Dongfang Li as non-executive directors, and Dr. Jian Ji, Mr. Hongze Liang and Ms. Yun Qiu as independent non-executive directors.